Hypertension and Migraine in the Northern Manhattan Study
Overview
Social Sciences
Authors
Affiliations
Objective: To investigate the association between migraine and hypertension in the Northern Manhattan Study (NOMAS), a multiethnic community-based sample.
Design: Cross-sectional cohort study.
Participants: 1338 NOMAS participants (mean age 68.1 ± 9.6 years, 37% male, 15% non-Hispanic White, 19% non-Hispanic Black, 67% Hispanic).
Setting: Northern Manhattan community.
Intervention: Participants were assessed for migraine symptoms using a self-report questionnaire based on criteria from the International Classification of Headache Disorders. Hypertension was defined as blood pressure ≥140/90 mm Hg, the patient's self-reported hypertension, or use of anti-hypertensive medications. Duration (≤9 years vs >9 years) and control (BP<140/90) of hypertension were examined. We estimated the association between hypertension and migraine (overall and with/without aura) using logistic regression, adjusting for sociodemographic and vascular risk factors.
Results: The majority of participants (80%) had no migraine, 6% had migraine with aura, and 15% had migraine without aura. Hypertension was present in 76% of the study population (7% had controlled hypertension ≤9 years duration, 5% controlled hypertension >9 years duration, 41% uncontrolled hypertension ≤9 years duration, 23% uncontrolled hypertension >9 years duration). Hypertension was associated with migraine (OR: 1.76, 95% CI: 1.21-2.54), both with and without aura. This association was particularly apparent for those with uncontrolled and long duration hypertension.
Conclusion: Hypertension, particularly uncontrolled and of long duration, is associated with migraine, both with and without aura, in a predominantly Hispanic community-based cohort.
Arterial hypertension in the chronic evolution of migraine: bystander or risk factor? An overview.
Mazzacane F, Vaghi G, Ramusino M, Perini G, Costa A J Headache Pain. 2024; 25(1):13.
PMID: 38311745 PMC: 10840219. DOI: 10.1186/s10194-024-01720-7.
Maghbooli M, Jameshorani M, Afshar S, Kamali K Curr J Neurol. 2023; 20(4):190-201.
PMID: 38011412 PMC: 9107570. DOI: 10.18502/cjn.v20i4.8344.
Prepregnancy Migraine, Migraine Phenotype, and Risk of Adverse Pregnancy Outcomes.
Purdue-Smithe A, Stuart J, Farland L, Kang J, Harriott A, Rich-Edwards J Neurology. 2023; 100(14):e1464-e1473.
PMID: 36657989 PMC: 10104618. DOI: 10.1212/WNL.0000000000206831.
Kang E, Prager O, Lublinsky S, Oliveira-Ferreira A, Reiffurth C, Major S J Cereb Blood Flow Metab. 2022; 43(2):210-230.
PMID: 36329390 PMC: 9903222. DOI: 10.1177/0271678X221135085.
Mechanotransduction: Exploring New Therapeutic Avenues in Central Nervous System Pathology.
Rocha D, Carvalho E, Relvas J, Oliveira M, Pego A Front Neurosci. 2022; 16:861613.
PMID: 35573316 PMC: 9096357. DOI: 10.3389/fnins.2022.861613.